Digital Health for Immune-Mediated Inflammatory Conditions

Millions of people worldwide suffer from immune-mediated, inflammatory conditions (IMIDs) such as rheumatoid arthritis, atopic dermatitis, psoriasis, ulcerative Colitis, and multiple sclerosis, to name a few. While there are still a lot of challenges in  patient care, a series of promising new treatments are making their way to market, and the near future is an exciting time for patients. As pharma companies prepare to launch these new therapies, digital health companies have the opportunity to harness the momentum and become part of these drugs’ commercialization plans.